MwanzoSAVA • NASDAQ
add
Cassava Sciences Inc
Bei iliyotangulia
$ 2.83
Bei za siku
$ 2.76 - $ 2.91
Bei za mwaka
$ 2.23 - $ 42.20
Thamani ya kampuni katika soko
135.53M USD
Wastani wa hisa zilizouzwa
9.63M
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | — | — |
Matumizi ya uendeshaji wa biashara | 14.05M | 228.51% |
Mapato halisi | -27.94M | -8.94% |
Kiwango cha faida halisi | — | — |
Mapato kwa kila hisa | -0.58 | 4.92% |
EBITDA | -31.46M | -14.47% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 148.98M | 4.66% |
Jumla ya mali | 223.75M | 29.69% |
Jumla ya dhima | 57.11M | 227.98% |
Jumla ya hisa | 166.64M | — |
hisa zilizosalia | 48.11M | — |
Uwiano wa bei na thamani | 0.81 | — |
Faida inayotokana na mali | -33.94% | — |
Faida inayotokana mtaji | -44.60% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -27.94M | -8.94% |
Pesa kutokana na shughuli | -18.30M | 31.04% |
Pesa kutokana na uwekezaji | elfu -17.00 | 22.73% |
Pesa kutokana na ufadhili | 0.00 | -100.00% |
Mabadiliko halisi ya pesa taslimu | -18.31M | 29.80% |
Mtiririko huru wa pesa | -50.28M | -174.35% |
Kuhusu
Cassava Sciences is an American pharmaceutical company based in Austin, Texas. The company was developing simufilam, an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials.
In June 2024, the United States Department of Justice charged an advisor to Cassava Sciences, Hoau-Yan Wang, with fraud over research results related to the experimental drug. Less than a month later, the president, chief executive officer and chairman of the board, Remi Barbier, resigned along with Lindsay Burns, his wife, who was a Cassava senior vice president and Wang's co-author. The U.S. Securities and Exchange Commission filed fraud charges in September 2024 against Cassava, Barbier, Burns and Wang. The parties did not admit wrongdoing, but a settlement of the SEC charges, pending court approval, would fine Cassava $US40 million, Barbier $175 thousand, Burns $85 thousand and Wang $50 thousand.
Cassava was founded in 1998 by Remi Barbier as Pain Therapeutics, Inc., changing its name in 2019. Wikipedia
Ilianzishwa
1998
Makao Makuu
Tovuti
Wafanyakazi
29
